Ivemend

RSS

fosaprepitant

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Ivemend and why it is authorised in the EU

Ivemend is a medicine for preventing nausea (feeling sick) and vomiting caused by chemotherapy cancer medicines.

It is used in adults and children from 6 months of age who are undergoing chemotherapy known to cause moderate or severe nausea and vomiting.

It contains the active substance fosaprepitant.

This EPAR was last updated on 30/07/2018

Authorisation details

Product details
Name
Ivemend
Agency product number
EMEA/H/C/000743
Active substance
fosaprepitant
International non-proprietary name (INN) or common name
fosaprepitant
Therapeutic area (MeSH)
  • Vomiting
  • Cancer
Anatomical therapeutic chemical (ATC) code
A04AD12
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
11/01/2008
Contact address

Waarderweg 39
2031 BN Harlem
The Netherlands

Product information

23/07/2018 Ivemend - EMEA/H/C/000743 - T/0039

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti emetics and antinauseants

Therapeutic indication

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.

Ivemend 150 mg is given as part of a combination therapy.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating